Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study

Leukemia Research

Volumn 37, Issue 2, 2013, Pages 162-168

  Besses, Carlos ^a   Kiladjian, Jean Jacques ^b   Griesshammer, Martin ^c   Gugliotta, Luigi ^d   Harrison, Claire ^e   Coll, Ruth ^f   Smith, Jonathan ^f   Abhyankar, Brihad ^g   Birgegård, Gunnar ^f  

^a HOSPITAL DEL MAR   (Spain)

^b SAINT LOUIS HOSPITAL   (France)

^c KLINIKUM MINDEN   (Germany)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^f Shire Pharmaceuticals   (United Kingdom)

^g UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anagrelide; Cytoreductive treatment; Essential thrombocythemia; Hydroxycarbamide; Interferon

Indexed keywords

ANAGRELIDE; BUSULFAN; HYDROXYUREA; INTERFERON; PHOSPHORUS 32; PIPOBROMAN; THROMBOREDUCTIN; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; EUROPE; FEMALE; GEOGRAPHIC DISTRIBUTION; HIGH RISK PATIENT; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHASE 4 CLINICAL TRIAL; PREGNANCY; PREGNANCY OUTCOME; PRESCRIPTION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTHEMIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; QUINAZOLINES; RISK FACTORS; THROMBOCYTHEMIA, ESSENTIAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872413434     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.11.004     Document Type: Article

References (29)

1. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. WHO classification of tumours of haemopoietic and lymphoid tissues 2008, IARC Press. 4th ed.
2. Brodmann S., Passweg J.R., Gratwohl A., Tichelli A., Skoda R.C. Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol 2000, 79(6):312-318.
3. Passamonti F., Rumi E., Pungolino E., Malabarba L., Bertazzoni P., Valentini M., et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004, 117(10):755-761.
4. Barbui T., Thiele J., Passamonti F., Rumi E., Boveri E., Ruggeri M., et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011, 29(23):3179-3184.
5. Barbui T., Barosi G., Birgegard G., Cervantes F., Finazzi G., Griesshammer M., et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011, 29(6):761-770.
6. Tefferi A., Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011, 29(5):573-582.
7. European Medicines Agency. Summary of Product Characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000480/WC500056557.pdf.
8. Barbui T., Barosi G., Grossi A., Gugliotta L., Liberato L.N., Marchetti M., et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004, 89(2):215-232.
9. Petrides P, Griesshammer M, Lengfelder E. Essential (or primary) thrombocythemia (ET) (German guidelines). Available from: http://www.dgho-onkopedia.de/onkopedia/leitlinien/essentielle-oder-primaere-thrombozythaemie-et.
10. Murphy S., Peterson P., Iland H., Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997, 34(1):29-39.
11. Reilly J.T. Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists. Hematology 2009, 14(1):1-10.
12. Spivak J.L., Hasselbalch H. Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther 2011, 11(3):403-414.
13. Seror J., Sentilhes L., Lefebvre-Lacoeuille C., Marpeau L. Interferon-alpha for treatment of essential thrombocythemia during pregnancy: case report and review of the literature. Fetal Diagn Ther 2009, 25(1):136-140.
14. Nordic MPD Study Group. Guidelines for the diagnosis and treatment of patients with polycythemia vera, essential thrombocythemia and primary myelofibrosis. Available from: http://www.nmpn.org/files/NMPD_guidelines_2009revision_pub.pdf.
15. Hellenic Society of Haematology Treatment of common haematologic diseases. J Hellenic Soc Haematol 2011, 2(Suppl. 1).
16. Kiladjian J.J., Chevret S., Dosquet C., Chomienne C., Rain J.D. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011, 29(29):3907-3913.
17. Harrison C.N., Bareford D., Butt N., Campbell P., Conneally E., Drummond M., et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010, 149(3):352-375.
18. Harrison C.N., Campbell P.J., Buck G., Wheatley K., East C.L., Bareford D., et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005, 353(1):33-45.
19. Murphy S., Iland H., Rosenthal D., Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol 1986, 23(3):177-182.
20. Barosi G., Besses C., Birgegard G., Briere J., Cervantes F., Finazzi G., et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 2007, 21(2):277-280.
21. Gugliotta L., Tieghi A., Tortorella G., Scalzulli P.R., Ciancia R., Lunghi M., et al. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leuk Res 2011, 35:1557-1563.
22. Kornblihtt L.I., Vassallu P.S., Heller P., Molinas F.C. Treatment of essential thrombocythemia with anagrelide: a ten-year experience. Medicina (B Aires) 2002, 62(3):231-236.
23. Penninga E., Jensen B.A., Hansen P.B., Clausen N.T., Mourits-Andersen T., Nielsen O.J., et al. Anagrelide treatment in 52 patients with chronic myeloproliferative diseases. Clin Lab Haematol 2004, 26(5):335-340.
24. Petrides P.E., Beykirch M.K., Trapp O.M. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol 1998, 61(2):71-76.
25. Campbell P.J., Maclean C., Beer P.A., Buck G., Wheatley K., Kiladjian J.J., et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood 2012, 120(7):1409-1411.
26. Carobbio A., Finazzi G., Guerini V., Spinelli O., Delaini F., Marchioli R., et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007, 109(6):2310-2313.
27. Palandri F., Catani L., Testoni N., Ottaviani E., Polverelli N., Fiacchini M., et al. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol 2009, 84(4):215-220.
28. Palandri F., Polverelli N., Catani L., Ottaviani E., Baccarani M., Vianelli N. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol 2011, 90(8):933-938.
29. Wolanskyj A.P., Schwager S.M., McClure R.F., Larson D.R., Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006, 81(2):159-166.